Clinical trial
A Phase I, Double-Blind, Randomized, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of NNZ-2566 in Healthy Subjects, Following Oral Administration
NCT01420042 is registered in ClinicalTrials.gov with Neuren Pharmaceuticals Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Double-Blind, Randomized, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of NNZ-2566 in Healthy Subjects, Following Oral Administration
- Lead sponsor
- Neuren Pharmaceuticals Limited
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 29, 2012
- Completion date
- September 30, 2012
- Enrollment
- 24 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.